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Protection of the enzyme acetylcholinesterase
(AChE) from the toxic effects of organophosphate
insecticides and chemical warfare agents (OPs)
may be provided by inhibitors that bind at the
peripheral binding site (P-site) near the mouth of
the active-site gorge. Compounds that bind to this
site may selectively block access to the acylation
site (A-site) catalytic serine for OPs, but not ace-
tylcholine itself. To identify such compounds, we
employed a virtual screening approach using AUTO-
DOCK 4.2 and AutoDock Vina, confirmed using
compounds experimentally known to bind specifi-
cally to either the A-site or P-site. Both programs
demonstrated the ability to correctly predict the
binding site. Virtual screening of the NCI Diversity
Set II was conducted using the apo form of the
enzyme, and with acetylcholine bound at the crys-
tallographic locations in the A-site only and in
both and A- and P-sites. The docking identified 32
compounds that were obtained for testing, and
one was demonstrated to bind specifically to the
P-site in an inhibitor competition assay.
Key words: acetylcholine, acetylcholinesterase, AChE, docking, vir-
tual screening
Abbreviations: AChE, acetylcholine esterase; OP, organophos-
phate; DMSO, dimethyl sulfoxide; NCI, National Cancer Institute.
Received 10 December 2010, revised 14 March 2011 and accepted for
publication 28 May 2011
Acetylcholinesterase (AChE) terminates synaptic neuromuscular
transmission by hydrolyzing the neurotransmitter acetylcholine (1).
One focus of AChE research lies in the development of new drugs
that could prevent and ⁄ or treat poisoning from organophosphates
(OPs), toxic agents commonly used in insecticides as well as in
chemical warfare agents (2). OP poisoning causes the inactivation
of AChE that prevents synaptic transmission, leading to muscle
paralysis, hypertension, and malfunction of various organ systems,
ultimately leading to death.
Two ligand-binding sites in AChE have been identified, the acylation
site (A-site) at the base of a deep active-site gorge and the periph-
eral site (P-site) near the gorge entrance through which ligands must
pass on their way to the A-site (3–5). Figure 1 shows the binding
gorge of human AChE with acetylcholine modeled into both the A-
site (green) and P-site (pink) as described in Methods. OPs are toxic
because they covalently react with S203 in the A-site. Wilson and
Ginsburg (6,7) conceived complementary oxime compounds that
could re-activate OP-poisoned AChE. These drugs serve as defenses
against OP toxicity, but they work only on OP-inactivated AChE. It
would be beneficial to develop prophylactic drugs that prevent AChE
from interacting with OPs in the first place, and our objective is to
design drug-like compounds to serve this function. One strategy is to
obtain small molecules that bind at or near the AChE P-site. Such
molecules could be modified, in principle, to sterically discriminate
access to the A-site in a way that still allows entry of acetylcholine
but limits the entrance of the larger OPs. This is a challenging task.
While a competitive inhibitor that binds to the A-site would reduce
the irreversible OP inactivation rate, it would equally reduce the rate
of acetylcholine hydrolysis and provide no benefit. The binding of a
ligand X to the AChE P-site is known to decrease the association
and dissociation rate constants for the binding of a ligand Y to the
A-site by factors of up to 400 (5,8), and it is this feature that we
propose to exploit in designing a P-site ligand that would selectively
block OP association with the A-site. Such a ligand would need very
high affinity (pM) for the P-site to effectively block OP inactivation,
and a strategy designed to evolve a series of lead compounds with
progressively higher affinity is necessary. Here we report on our first
steps in such an evolution.
The development of structure–activity relationships for ligands that
bind specifically to the AChE P-site is in its infancy. Because of a
possible AChE P-site role in promoting amyloid-b aggregation in Alz-
heimer's disease (9), in silico screening of a limited 270-member
library of compounds was initiated to identify new ligands with P-site
specificity (10,11). Several identified compounds as well as tetrahy-
drocannabinol (9) were shown experimentally to bind to the P-site.
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We used a virtual screening approach to identify P-site ligands from
a much larger library of compounds. To establish the ligand docking
procedures used to screen the library, we selected several com-
pounds known to bind to either the A-site or the P-site by X-ray
crystallography. These were first redocked back into their original
crystal structures with two docking programs, AutoDock Vina (12)
and AUTODOCK version 4.2 (13). These compounds were then docked
into human AChE to confirm that the docking programs could iden-
tify a preference for the correct site. Finally, virtual screening was
used to identify compounds that bind preferentially to the P-site,
and still allow acetylcholine to bind to the A-site of AChE. The NCI
Diversity Set II (14) was first docked using Vina in combination with
a consensus scoring approach, and after an initial round of testing,
was docked using AUTODOCK 4.2. Candidate compounds predicted to
show selective P-site binding were obtained from the NCI and
tested experimentally with an AChE inhibitor-competition assay that
can distinguish between inhibitor binding to the A-site or P-site.
Methods
Preparation of crystal structures
The structure of human acetylcholinesterase (AChE) was derived
from the crystal structure of the AChE complexed with fasciculin-II
deposited in the RCSB Protein Databank (15) (PDB id:1B41) by Kry-
ger and co-workers (16); only the AChE was retained for our model-
ing studies. The locations of the A- and P-sites were defined from
the crystal structure of the S203A mutant of mouse AChE com-
plexed with acetylcholine (17) (PDB id: 2HA4), which shows one
molecule of acetylcholine in each site. The 1B41 and 2HA4 struc-
tures were superimposed, and the acetylcholine molecules from
2HA4 were merged with AChE from 1B41. This formed our model
of human AChE complexed with acetylcholine used in subsequent
studies.
Docking controls
Crystal structures of several additional AChE-ligand complexes have
been deposited in the PDB, including complexes at the A-site with
edrophonium (18) (2ACK) or tacrine (19) (1ACJ) and complexes at
the P-site with thioflavin T (20) (2J3Q), decidium (21) (1J07), propidi-
um (21) (1N5R), methylene blue (22) (2W9I), or aflatoxin B1(23)
(2XI4). Crystal structures of AChE complexes involving ligands that
span both sites also have been obtained, but these ligands are not
of interest in this study and were not examined. These structures
all were obtained as complexes with Torpedo californica AChE
(TcAChE) or Mus musculus (MmAChE). The complexes were super-
imposed with our human model of AChE, and therefore, all coordi-
nates are in relation to 1B41, with the A-site and P-site defined by
the acetylcholines originally from 2HA4. These ligands, shown in
Figure 2, were used to test our docking procedures. In each case,
the ligand was removed from the original structure and redocked
into that structure with a docking box centered on the original
ligand position and measuring 25.2  on each side, sufficiently
large to encompass the ligands in this study. For the redocking con-
trols, all crystal waters were retained.
Ability to reproduce crystal structure binding mode was assessed by
molecular volume overlap, presented as a percentage of the volume
of the X-ray ligand. For these calculations, we used ROCS (OpenEye
Scientific Software, Sante Fe, NM, USA) to determine the absolute
volume and divided the volume overlap of a ligand with itself to
determine percentages. Overlap close to 100% can be interpreted
as correct prediction of binding mode, while mid-range overlaps typ-
ically bind in the correct site with an incorrect conformation, and
low values indicate binding in a different site.
Additionally, each of these ligands was docked into our model of
human AChE under three different conditions: apo-AChE, with both
the A- and P-sites free; AChE with the acetylcholine bound in the
Figure 1: The AChE catalytic site is a narrow active-site gorge some 20  deep (yellow) that penetrates nearly to the center of the
65 kDa catalytic subunits. Near the base of the gorge is the A-site where H447, E334, and S203 (red) participate in a triad that catalyzes
the transient acylation and deacylation of S203 during each substrate turnover. The P-site is spanned by residues W286 near the mouth of
the gorge and D74 near a constriction at the boundary between the P-site and the A-site. (B) Acetylcholine modeled into the A-site (green)
and P-site (pink) as described in Methods.
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A-site; and AChE with acetylcholine bound at both the A-site and
P-site. This docking was intended to demonstrate the ability of the
docking procedure to correctly produce the known binding site of
each ligand. The docking was performed with both Vina and AUTO-
DOCK 4.2 using a docking box located at the center of mass of the
two modeled acetylcholines (119.1, 109.1, )133.1), measuring
51.2  on each side, more than large enough to encompass both
sites. In this case, the overlap volume was calculated as overlap
with the A- and P-site modeled acetylcholines.
Virtual screening
Virtual screening of the NCI Diversity Set II (14), which consists of
1364 diverse compounds selected from the full library of 140 000
compounds, was docked to identify candidate drug-like compounds
that might complementarily bind at or near the P-site of human
AChE. Three sets of dockings were performed: apo-AChE, with both
the A- and P-site free; AChE with the acetylcholine bound in the A-
site; and AChE, with acetylcholine bound at both the A- and P-sites.
These conditions were selected to distinguish compounds that have
a preference for each specific site, as well as those that bind out-
side either site. Again, the docking box was centered at the center
of mass of the two acetylcholine molecules and measured 51.2 
on each side to allow docking to any site. For each compound in
each of the different docking protocols, the 20 top-scoring poses of
the complexes were retained. The docking simulations were per-
formed on the IBM cluster at the Washington University High-Per-
formance Computing Center in Saint Louis.
A total of 27 280 poses (20 top-scoring poses for 1364 compounds)
obtained from each of the docking protocols were re-ranked using a
consensus scoring approach (24–26) that has been successful in vir-
tual screening of other targets (27,28). This technique should elimi-
nate any particular bias and increase confidence in the ranking of
binding affinities and ⁄ or docking scores used as criteria to select
compounds for experimental testing. In this case, we used the Vina
score, X-Score (29), and CSCORE (30). Compounds were selected
that had poses ranked in the top 1500 with all three scoring rou-
tines. These compounds were limited to £10 rotatable bonds, and
filtered by Lipinski's 'Rule of 5': MW < 500, logP < 5, h-bond accep-
tors < 10, h-bond donors < 5; to help insure bioavailability (31), and
selected compounds were examined in enzymatic assays with AChE.
The dockings of all 1364 NCI compounds were also conducted with
AUTODOCK version 4.2, with or without acetylcholine bound to the
A-site alone or to both the A- and P-sites. Parameters used for the
dockings were defaults except for the following: npts of 256 in
each dimension, grid spacing of 0.200, ls_search_freq of 0.2,
ga_run of 20, ga_num_evals of 10 000 000. The center of the two
acetylcholine molecules was set as the grid center for docking, with
a docking box 51.2  on each side.
Inhibition of AChE hydrolysis of
acetylthiocholine at low substrate
concentrations
Recombinant human AChE was expressed as a secreted, disulfide-
linked dimer in Drosophila S2 cells and purified as outlined previously
(32). Recrystallized methylene blue was a gift of Dr. Lev Weiner and
Dr Esther Roth at the Weizmann Institute in Rehovath, Israel, and
concentrations were assigned by absorbance at 663 nm with
e663 nm = 74 000 M)1 cm)1. Thioflavin T and edrophonium were
Figure 2: Ligands with crystal structures of the AChE-ligand complexes.
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prepared as described previously (33). Substrate hydrolysis rates v
were measured with acetylthiocholine and 5,5¢-dithiobis-(2-nitroben-
zoic acid) (DTNB, 0.33 mM) in a coupled Ellman reaction in assay
buffer (20 mM sodium phosphate buffer (pH 7.0) and 0.02% Triton
X-100 unless otherwise noted) at 25C (34).
The assay used here to assess inhibition of AChE activity measures
the second-order hydrolysis rate constant kE obtained when the
substrate concentration [S] is much less than the Michaelis con-
stant Kapp (34). Under these conditions, Scheme 1 includes all rele-
vant enzyme species. This scheme assumes that substrate binds
initially to the P-site (E SP) before progressing to the A-site (ES)
where it is hydrolyzed to products P, and it can be applied both to
inhibitors that bind at the A-site (LP = I, and 1 ⁄ i = 0) and to inhibi-
tors that bind at the P-site (LP = I P) with dissociation constants KI.
Under these second-order conditions, substrate hydrolysis rates
v = kE[E]tot[S], where [E]tot is the total enzyme concentration, and kE
is measured from eqn 1 (35).
½S ¼ ½S0ezt ð1Þ
In eqn 1, z = kE[E]tot and t is the time after mixing E and S.
Because acetylthiocholine is hydrolyzed by AChE at nearly diffusion-
controlled rates, inhibitor binding to either the A- or P-sites results
in an expression for the ratio of kE in the absence of inhibitor








If a series of assays are conducted with a fixed concentration of
one inhibitor I1 together with varying concentrations of a second
inhibitor I2, kE in the presence of both inhibitors (here denoted
kE + I2) relative to kE when only I1 is present (here denoted








þ ½I2 1þ ½I1K12
  ð3Þ
In this equation, K1, K2, and K12 are the equilibrium dissociation
constants for I1 with E, I2 with E, and I1 with the EÆI2 complex,
respectively. The value of [I1] ⁄ K12 will be significantly >0 only if the
ternary complex EÆI1ÆI2 can form, and this analysis, thus, can be
used to detect ternary complex formation.
Assay of NCI diversity set compounds
Compounds were dissolved in dimethyl sulfoxide (DMSO) at 10–
50 mM and diluted (1:100) into assay buffer. If the compound was
insoluble after dilution, the DMSO stock was diluted (1:10) into
methanol and then diluted further (1:10) into assay buffer. The
assay solvent for the control without a compound was matched to
that with compound. AChE activity was essentially unaffected by
10% methanol but was inhibited about 2-fold in the presence of




The AChE binding sites of the compounds presented in Figure 2 are
known from X-ray crystallography, and for each, the compound was
removed from the structure and redocked with Vina or AUTODOCK
4.2. The ability to reproduce the X-ray binding mode is presented
as the percent overlap of the docked ligand with the X-ray binding
mode in Table 1. Docking with Vina was more successful at locat-
ing the ligand within the original binding site than AUTODOCK 4.2, as
each docked ligand had a higher overlap with the X-ray structure.
However, lack of complete overlap for most ligands describes at
least a shift in position of the docked compounds, and some mole-
cules, such as tacrine, are flipped within their correct site. The
ligand ranking by docking energy agrees for the two programs
except for propidium and decidium, likely due to the difficulty in
docking these flexible molecules. For AUTODOCK 4.2, docking acetyl-
choline to 2HA4 with both copies of the crystallographic acetylcho-
line ligand removed results in consistent docking to only the A-site,
even though both the A- and P-sites were available. Docking to
AChE with the A-site occupied by the crystallographic acetylcholine
results in the second acetylcholine docking reliably to the P-site.




















Scheme 1: Enzyme species considered in kinetic model.
Table 1: Redocking of compounds with known crystal structures
PDB ID










Tacrine 1ACJ 98.9 )9.5 61.3 )9.0
Edrophonium 2ACK 94.6 )6.2 96.5 )6.6
P-site ligands
Thioflavin T 2J3Q 81.8 )7.9 27.8 )7.2
Propidium 1N5R 91.4 )6.8 13.1 )8.6
Decidium 1JO7 55.0 )6.2 42.9 )10.7
Methylene Blue 2W9I 55.9 )8.5 42.5 )7.7
Aflatoxin B1 2XI4 98.6 )9.6 97.0 )9.1
Acetylcholine A-site 2HA4 83.7 )4.8 48.2 )5.5
Acetylcholine P-site 2HA4 65.3 )4.3 68.9 )3.8
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Using Vina, acetylcholine is docked into both the A-site and P-site
if they are unoccupied.
Crystal water molecules play an important role in accurately repro-
ducing crystal structures in docking. This was noted specifically for
AChE by Dickerson and co-workers (10), who observed that crystal
waters greatly improved docking results for propidium and decidium.
We observe this same behavior with several ligands, including ace-
tylcholine and edrophonium shown in Figure 3. Without crystal
waters, (Figure 3A) edrophonium docks to the A-site, but only par-
tially overlaps with the crystal structure binding mode (28.8% vol-
ume overlap). The inclusion of only five of the crystal structure
waters (Figure 3B) in the A- and P-sites results in a docked struc-
ture that much more closely matches the crystal structure ligand
(86.7% overlap).
As A-site waters in AChE are well-known, inclusion of explicit
waters in docking would be preferred. However, given the diverse
chemotypes in our compound database, it is not possible to know
prior to docking which compounds may interact with or displace the
water molecules. Therefore, as an additional control calculation, we
docked these same known ligands to human AChE with all waters
removed to assess the ability of Vina and AUTODOCK 4.2 to correctly
predict the preferred binding site for each ligand under virtual
screening conditions.
Docking with human AChE
The three-dimensional structures of TcAChE, MmAChE, and human
AChE are very similar, and most features of the active-site gorge
are conserved between the species. Nevertheless, to confirm that
the results obtained with TcAChE and MmAChE also apply to
human AChE, docking with Vina and AUTODOCK 4.2 to human AChE
was repeated for all the ligands in Figure 2. Docking trials were
performed with three different conditions: apo-AChE, with both the
A- and P-site free; AChE with the acetylcholine bound in the A-site;
and AChE with acetylcholine bound at both the A- and P-site.
Docking energies for both Vina and AUTODOCK 4.2 are presented in
Table 2 for the apo-AChE docking (no bound acetylcholine). Binding
in the correct site is described by the percent overlap with acetylc-
holines in the A-site and P-site modeled into 1B41 through superpo-
sition of 2HA4. A measurable percent overlap indicates it is unlikely
that the modeled acetylcholine and the docked ligand could bind
simultaneously in the given binding mode. When only a partial over-
lap is observed, typically the ligand is docked immediately adjacent
to the modeled acetylcholine.
All ligands are predicted to bind to the known preferred site except
for tacrine docking by Vina, which was docked to the P-site. Decidi-
um docked by Vina spans both sites, but is predominantly located
in the P-site. Acetylcholine was docked by both programs into both
the A- and P-sites, with a slight preference in predicted energy for
the A-site, although none exactly reproduces the crystal structure
binding mode. As with the redocking control, the ranking by docking
energy agrees between Vina and AUTODOCK 4.2, with the exception
of propidium and decidium.
The docking to human AChE with acetylcholine modeled into either
the A-site or both the A- and P-sites produces similar results (data
not shown). As each site is occupied, the docking algorithms will
identify another binding location, but with less favorable energy. It
A B
Figure 3: Docking of edrophonium into Torpedo apo-AChE using
AUTODOCK 4.2 (A) with crystal waters removed; (B) with crystal
waters retained. Crystal structure ligand and water in thin lines and
docked results in thick lines.
Table 2: Docking control ligands into human apo-AChE














Tacrine 0 84.6 )8.5 65.8 0 )8.7
Edrophonium 65.8 0 )6.3 62.2 0 )6.6
P-site ligands
Thioflavin T 0 73.3 )8.0 4.6 25.2 )7.6
Propidium 0 15.9 )7.2 0 65.8 )10.2
Decidium 46.2 72.7 )9.1 0 82.9 )10.4
Methylene blue 0 85.7 )7.9 4.0 44.9 )7.2
Aflatoxin B1 0 84.0 )9.0 0 100 )8.9
Acetylcholine A-site 59.7 0 )4.4 43.5 0 )4.9
Acetylcholine P-site 0 29.2 )3.9 0 33.7 )4.8
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should be noted that the percent overlaps in Table 1 are with the
crystallographic ligands themselves but in Table 2 are with modeled
acetylcholine originally from the 2HA4 crystal structure. Therefore,
these values are not directly comparable except for acetylcholine
itself. We do observe a decrease in percent overlap for acetylcho-
line between the redocking (Table 1) and human docking (Table 2),
but this is expected because of the removal of crystal structure
water from human AChE.
Overall, these docking controls suggest that both the Vina and
AUTODOCK 4.2 programs may be useful for virtual screening for P-
site binders of AChE. Vina more accurately predicted crystal struc-
ture binding modes, but AUTODOCK 4.2 was better at predicting the
correct binding site. The exact orientations of some docked poses
were not always reproduced, but this is not surprising considering
the limitations in the scoring functions and search algorithms used
in docking. To minimize some of these limitations, our Vina virtual
screening protocol employed an established consensus scoring
approach (27,28) that incorporates X-Score and CSCORE with the
predicted binding energy from docking.
Identifying the binding site
The inhibition of second-order, substrate-hydrolysis rates kE as mea-
sured with eqns 2 and 3 provides a convenient framework for
experimentally examining the interaction of an inhibitor with free
AChE. The assays are designed to assign the binding location of an
unknown inhibitor by examining its competition with inhibitors
whose binding sites are known from X-ray crystallography. The
approach is illustrated in Figure 4, where the A-site inhibitor edro-
phonium and the P-site inhibitor thioflavin T are employed as the
known inhibitors and methylene blue is analyzed as the unknown
inhibitor. The data in Figure 4A show that kE[I] = 0 ⁄ kE + I with all
three inhibitors has a linear dependence on the inhibitor concentra-
tion [I], in accord with eqn 2. In this case, the simplified inhibitor-
competition analysis in eqn 3 can be applied (33,34,36) to deter-
mine whether the unknown inhibitor binds to the A- and ⁄ or P-sites.
The analysis is designed to detect any ternary complex formed
when the unknown inhibitor and the inhibitor with a known binding
site are added to AChE simultaneously. The data with methylene
blue alone are plotted in the reciprocal form kE + I ⁄ kE[I] = 0 in Fig-
ure 4B,C to emphasize KI as the IC50, or inhibitor concentration at
which kE + I ⁄ kE[I] = 0 was decreased by 50%. When a fixed concen-
tration of edrophonium was included in the assays, the IC50 for
methylene blue was shifted slightly to the right, indicating some
competition between the two inhibitors. The affinity of methylene
blue or edrophonium in the ternary complex decreased by a factor
of 3.3 relative to their affinities in their respective binary complexes
with the free enzyme, a small change that indicated slight steric
overlap between the two binding sites. For comparison, the relative
affinities of edrophonium and thioflavin T in the ternary complex
with AChE were virtually identical to those in their respective bin-
ary complexes (34), and thus, these two known standards show no
overlap between their binding sites. In contrast, the IC50 for methy-
lene blue in Figure 4C was shifted well to the right by the addition
of thioflavin T. One can calculate the extent of the shift that would
result from complete competition and no ternary complex formation
from the KI values of the inhibitors individually, and these calcu-
lated shifts are shown as the dotted lines in Figure 4B,C. Methy-
lene blue and thioflavin T essentially showed complete competition
in Figure 4C. These data indicate that methylene blue binds to the
AChE P-site in a fashion that is competitive with thioflavin T, but
slightly overlaps edrophonium bound at the A-site. This interpreta-
tion is confirmed by the P-site binding of methylene blue complexed
with AChE in the crystal structure 2W9I (22).
Virtual screening with Vina
Virtual screening of 1364 compounds that comprise the NCI Diversity
Set II was initially performed with AutoDock Vina in the presence of
Figure 4: (A) Inhibition of substrate hydrolysis by the A-site inhibitor edrophonium and the P-site inhibitors thioflavin T and methylene
blue. The substrate S was acetylthiocholine ([S]0 = 10 lM), and [E]tot was 0.31 nM (for [I] £ 5 lM) or 1.6 nM (for [I] ‡ 5 lM, not shown), and
the inhibitor I is indicated. Second-order rate constants kE were obtained with eqn 1 and the ratios kE[I] = 0 ⁄ kE + I were fitted to eqn 2. The
KI values obtained were 110 € 4 nM for methylene blue (), 0.43 € 0.02 lM for edrophonium (D), and 1.24 € 0.04 lM for thioflavin T (O). B,
C) Inhibitor competition assay for assignment of AChE binding-site specificity. Values of kE, with inhibitor I2 in the presence (D) or absence
(O) of inhibitor I1 as indicated, were obtained as described in Panel A, and the ratios kE + I2 ⁄ kE[I2] = 0 were fitted to eqn 3. K1 and K2 values
were set as the KIs from Panel A, and K12 was fitted. For edrophonium and methylene blue (panel B), the affinity in the binary complexes rel-
ative to that in the ternary complex was given by K12 ⁄ K1 = 3.3 € 0.3. For thioflavin T and methylene blue (panel C), K12 ⁄ K1 = 100 € 35. Dot-
ted lines were calculated with the same values of K1 and K2 but with [I1] ⁄ K12 fixed at 0.
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acetylcholine molecules at both the A- and P-sites, in an effort to
identify compounds that bound adjacent to the P-site. From consen-
sus scoring using Vina binding energies, X-Score and CSCORE fol-
lowed by Lipinski's-rule filtering, sixteen compounds with the highest
scores were identified. These compounds were then docked to the
human apo-AChE (with no acetylcholine bound to either the A- or P-
sites) to determine if P-site docking was maintained. Most of the
compounds shifted to bind predominantly at the P-site, while some
shifted sufficiently to span both the A- and P- sites.
All 16 compounds were obtained from the NCI for testing. Three
compounds were insoluble in the assay conditions, and eleven oth-
ers were inactive (<10% inhibition at 10 lM). Two compounds
shown in Figure 5 showed inhibition and were tested in the edro-
phonium competition assay to assess the extent to which they
block the A-site. The affinity of both the compounds in the ternary
complex with edrophonium and AChE decreased by a factor of >10
relative to their affinity in their respective binary complexes (Fig-
ure 5). This result indicated that the compounds overlapped strongly
with edrophonium bound at the A-site, in contrast to the binding
poses predicted by Vina. As the goal of this screening strategy was
to identify inhibitors that did not overlap with the A-site, these
compounds were not considered further.
A second round of virtual screening with Vina was also performed
with acetylcholine bound only at the A-site, in an attempt to iden-
tify compounds that bound specifically at the P-site. Six compounds
were predicted to bind at the P-site and were obtained for experi-
mental assay. All six were poorly soluble and were not considered
further.
Virtual screening with AUTODOCK 4.2
The docking-based virtual screening of NCI Diversity Set II was
repeated using AUTODOCK 4.2, again using apo-AChE and AChE with
acetylcholine in either the A-site alone or in both the A- and P-
sites. This protocol was developed to indicate which compound
bound preferentially at the A-site, P-site, or outside either site.
Twenty docking poses were generated and clustered, and com-
pounds with predicted binding affinities better than )7.0 kcal ⁄ mol
in each of the three docking runs were selected for further analysis
and visual inspection. Thirty-eight compounds met these criteria,
and sixteen were obtained from the NCI for experimental assay. Of
these, four were insoluble and the inhibition from ten others was
too low to be of interest (<20% inhibition at 50 lM compound).
Two compounds gave greater inhibition of AChE, and one
(NSC_358311) had sufficient solubility for analysis with the inhibitor
competition assay (Figure 6). Although the affinity of NSC_358311
for AChE was low (K2 = 100 lM), this assay indicated little over-
lap with the A-site, as NSC_358311 affinity in the ternary complex
with edrophonium and AChE decreased by a factor of about 2 rela-
tive to its affinity in the binary complex with AChE (Figure 6A).
Figure 5: Inhibitor competition assay for assignment of AChE binding-site specificity for compounds selected from NCI Diversity Set II. Val-
ues of kE, with inhibitors I1 and I2 as indicated, were obtained as described in the Figure. To maintain I2 solubility, assay buffer contained
1% dimethyl sulfoxide (DMSO) with 63 680 and 1% DMSO, 10% methanol with 146769. The ratios kE + I2 ⁄ kE[I2] = 0 were fitted to eqn 3, K1
was set from the Figure, and K2 values in the absence of edrophonium (O) were determined from eqn 3 for 63680 (280 € 13 nM) and
146769 (16 € 2 lM). K12 was then fitted in the presence of edrophonium (D). The affinity in the binary complexes relative to that in the ter-
nary complex with edrophonium (K12 ⁄ K1) was 19 € 2 for 63680 and 10 € 5 for 146769. Dotted lines were calculated with the same values of
K1 and K2 but with [I1] ⁄ K12 fixed at 0.
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However, no ternary complex involving NSC_358311, thioflavin T,
and AChE could be detected (1 ⁄ K12 = 0), which shows that
NSC_358311 binds only at the P-site. This is consistent with the
docking result in Figure 7, which shows complete overlap with the
P-site acetylcholine. This predicted binding mode would also allow
a ternary complex with NSC_358311 bound at the P-site and acetyl-
choline at the A-site. Figure 7 also shows that NSC_358311 docks
with the same binding mode both to apo-AChE (panel A) and AChE
with modeled acetylcholine occupying the A-site (panel B). In this
docked conformation, NSC_358311 has 65% volume overlap with
the P-site (as defined previously) and zero overlap with the A-site.
Conclusion
Virtual screening of compounds with specificity for the AChE P-site
with AutoDock Vina and AUTODOCK 4.2 was tested with compounds
whose specificity for the P-site was known from X-ray crystallogra-
Figure 6: Inhibitor competition assay for assignment of AChE binding-site specificity for NSC_358311. Values of kE, with inhibitors I1 and
I2 as indicated, were obtained as described in Figure 5. To maintain I2 solubility, assay buffer contained 1% dimethyl sulfoxide and 10%
methanol. The ratios kE + I2 ⁄ kE[I2] = 0 were fitted to eqn 3, K1 values were set from Figure. 5, and a K2 value in the absence of I1 (O) was
determined from eqn 3 as 111 € 25 lM. K12 was then fitted in the presence of I1 (D). The affinity in the binary complexes relative to that in
the ternary complex (K12 ⁄ K1) was 2.4 € 1.1 with edrophonium, but was infinite with thioflavin T (i.e., the fitted line superimposed on the dot-
ted line calculated with the same values of K1 and K2 but with [I1] ⁄ K12 fixed at 0).
A B
Figure 7: NSC_358311 (colored by element) docked to A) apo-AChE, B) AChE with acetylcholine modeled at the A-site. Acetylcholine mol-
ecules from crystal structure 2HA4 are superimposed at the P-site (pink) and A-site (green).
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phy. The Vina and AUTODOCK 4.2 docking programs were then used for
virtual screening of compounds from the NCI Diversity database, and
they identified two different sets of candidates with potential P-site
specificity. However, testing of two candidates predicted by Vina with
an experimental inhibitor competition assay did not support this spec-
ificity. Virtual screening with AUTODOCK 4.2 identified NSC_358311,
which the experimental binding competition assay showed to bind
specifically to the P-site of AChE, while allowing a ligand to bind
simultaneously at the A-site. This molecule may provide a lead for
additional virtual screening, and as a good starting point for synthetic
modifications that limit access to the A-site in a way that still allows
entry of acetylcholine but limits the entrance of the larger OPs.
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